This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Alan Menter, MD
Division of Dermatology Baylor University Medical Center 3500 Gaston Ave Dallas, TX 75246

Arch Dermatol. 1995;131(2):226-227.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

The use of potent topical corticosteroids in the treatment of erythrodermic psoriasis is fraught with difficulties and complications. The report of Arbiser et al¹ in the June 1994 ''Cutting Edge'' should be viewed with caution in the light of large, previously published series that have not been referenced.^2,3 In these articles, the use of systemic or potent topical steroids was shown to be the most common trigger factor for erythrodermic psoriasis. There is no doubt that the use of potent topical steroids under occlusion, even in the shortterm as advocated by Arbiser et al, may give temporary relief but should not be considered the treatment of choice due to the potential for ''rebound.'' Of interest is that their first patient (''poorly compliant'') has had subsequent hospital admissions for his psoriasis following the course of treatment prescribed.

An erythrodermic protocol using cool baths, wet dressings, and low-potency topical steroids . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?